TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) filed its financial and operating results today for its fiscal quarter ended September 30, 2014.
Highlights for the quarter include:
•The Company completed the first stage of its Phase I study, the prescheduled SAD (single ascending dose) stage, on ATB-346.
Help employers find you! Check out all the jobs and post your resume.
